NCT05079152 Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 Status UNKNOWN Phase PHASE4
NCT05077202 A New Scoring Model to Diagnose COVID-19 Using Lung Ultrasound in the Emergency Department Status COMPLETED Phase N/A
NCT05069129 Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Status UNKNOWN Phase PHASE1/PHASE2
NCT05065892 Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes Status UNKNOWN Phase PHASE4
NCT05065879 Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes Status COMPLETED Phase PHASE4
NCT05063799 Pulmonary Rehabilitation After Pregnancy in COVID-19 Infection: A Case Report Status COMPLETED Phase NA
NCT05057923 The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Status COMPLETED Phase NA
NCT05057221 Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia Status TERMINATED Phase PHASE1/PHASE2
NCT05047016 Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY Status UNKNOWN Phase NA
NCT05045937 Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 Status UNKNOWN Phase N/A
NCT05045885 Safety and Feasibility of Percutaneous Dilatational Tracheostomy in Patients With Severe COVID-19 Supported by ECMO Status COMPLETED Phase N/A
NCT05042063 Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease Status COMPLETED Phase N/A
NCT05035589 The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia Status COMPLETED Phase N/A
NCT05035524 A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 Status UNKNOWN Phase NA